377 related articles for article (PubMed ID: 19414940)
41. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.
Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ
Trials; 2014 May; 15():158. PubMed ID: 24886272
[TBL] [Abstract][Full Text] [Related]
42. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Ferreira JP; Santos M; Almeida S; Marques I; Bettencourt P; Carvalho H
Eur J Intern Med; 2014 Jan; 25(1):67-72. PubMed ID: 24070521
[TBL] [Abstract][Full Text] [Related]
43. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
44. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
45. [Study of the month. The RALES study (randomized aldactone evaluation study].
Kulbertus H
Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
[TBL] [Abstract][Full Text] [Related]
46. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Tamirisa KP; Aaronson KD; Koelling TM
Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
[TBL] [Abstract][Full Text] [Related]
47. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
Berry C; McMurray JJ
Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
[TBL] [Abstract][Full Text] [Related]
48. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
49. Spironolactone therapy in heart failure patients with chronic kidney disease.
Lopes R; Lourenco P; Mascarenhas J; Azevedo A; Bettencourt P
Clin Cardiol; 2009 Oct; 32(10):597. PubMed ID: 19911355
[No Abstract] [Full Text] [Related]
50. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
[TBL] [Abstract][Full Text] [Related]
51. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
[TBL] [Abstract][Full Text] [Related]
52. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
[TBL] [Abstract][Full Text] [Related]
53. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
[TBL] [Abstract][Full Text] [Related]
55. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
Matsumoto Y; Mori Y; Kageyama S; Arihara K; Sugiyama T; Ohmura H; Yakushigawa T; Sugiyama H; Shimada Y; Nojima Y; Shio N
J Am Coll Cardiol; 2014 Feb; 63(6):528-36. PubMed ID: 24184249
[TBL] [Abstract][Full Text] [Related]
56. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
[TBL] [Abstract][Full Text] [Related]
57. Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction.
Ganda A; Weiner SD; Chudasama NL; Valeri AM; Jadoon A; Shimbo D; Radhakrishnan J
Clin Nephrol; 2012 May; 77(5):366-75. PubMed ID: 22551882
[TBL] [Abstract][Full Text] [Related]
58. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
Chan AK; Sanderson JE; Wang T; Lam W; Yip G; Wang M; Lam YY; Zhang Y; Yeung L; Wu EB; Chan WW; Wong JT; So N; Yu CM
J Am Coll Cardiol; 2007 Aug; 50(7):591-6. PubMed ID: 17692742
[TBL] [Abstract][Full Text] [Related]
59. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.
Cicoira M; Zanolla L; Rossi A; Golia G; Franceschini L; Brighetti G; Marino P; Zardini P
J Am Coll Cardiol; 2002 Jul; 40(2):304-10. PubMed ID: 12106936
[TBL] [Abstract][Full Text] [Related]
60. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients.
Flevari P; Kalogeropoulou S; Drakou A; Leftheriotis D; Panou F; Lekakis J; Kremastinos D; Vlahakos DV
J Hypertens; 2013 Jun; 31(6):1239-44. PubMed ID: 23552120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
